Morningside Healthcare Contraceptives

For more information about Bimizza^®, please click here for the prescribing information.

Bimizza^® – A low cost,^1—3 bioequivalent alternative to Mercilon^®4

• Bimizza^® is a monophasic combined oral contraceptive (COC) pill which contains 150 mcg desogestrel and 20 mcg ethinylestradiol³
• Bimizza^® contains the same active ingredients and has demonstrated bioequivalence to Mercilon^®, therefore, following appropriate patient assessment and review, it may be prescribed in place of Mercilon^®2—5
• Each pack of Bimizza^® contains 3 x blister strips of 21 tablets for 3 cycles of contraceptive cover⁶

Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.

Summary of Product Characteristics and Patient Information Leaflet

The links below will take you to the electronic Medicines Compendium (eMC). By clicking the links below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

Please click here to access the Summary of Product Characteristics

Please click here to access the Patient Information Leaflet

Risk Minimisation Materials

The links below will take you to the electronic Medicines Compendium (eMC). By clicking the links below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

Please click here to access the Prescriber Checklist, Patient Alert Card and Important Information for Women leaflet

Please click here to access a warning letter concerning the thromboembolism risk of combined hormonal contraceptives

Additional Prescriber Resources

Whether your patient is starting the pill for the first time, or you are talking to them about changing from their current brand of contraceptive to Bimizza^®, it can be useful to have information and materials to hand to counsel patients. The following assets can be downloaded/edited at your discretion for use during a consultation:

• Additional patient support leaflet from Morningside Healthcare
• Patient letter template for change of contraceptive brand

By clicking the link below you will leave the Morningside Healthcare Contraceptives website and be re-directed to an external site; Morningside Healthcare is not responsible for the content on external websites.

The full NICE Clinical Knowledge Summary for COCs, including UK Medical Eligibility Criteria may be found here.

 
References

1. UK drug tariff (Accessed April 2024)
2. NHS dm+d. Actual Medicinal Product (AMP) Mercilon 150microgram/20microgram tablets (Organon Pharma (UK) Ltd). Available at: https://dmd-browser.nhsbsa.nhs.uk/amp/view/8217 (accessed January 2024);
3. NHS dm+d. Actual Medicinal Product (AMP) Bimizza 150microgram/20microgram tablets (Morningside Healthcare Ltd). Available at: https://dmd-browser.nhsbsa.nhs.uk/amp/view/118811 (accessed January 2024);
4. MHRA. UK PAR Bimizza 150 microgram/20 microgram tablets. February 2015. Available at: https://mhraproductsproduction.blob.core.windows.net/docs/33446c8282edba466bfd797be04735e72eb54bca (accessed January 2024);
5. Organon Pharma (UK) Ltd. Mercilon Tablets. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1360/ (accessed January 2024);
6. NHS dm+d. Actual Medicinal Product Pack (AMPP) Bimizza 150microgram/20microgram tablets (Morningside Healthcare Ltd) 63 tablet 3 x 21 tablets. Available at: https://dmd-browser.nhsbsa.nhs.uk/ampp/view/138092 (accessed January 2024).

Mercilon^® chosen as a comparator as it is the license reference product for Bimizza^®.⁴